Na Ning, Li Heng, Xu Chengfang, Miao Bin, Hong Liangqing, Huang Zhengyu, Jiang Qiu
Department of Kidney Transplantation.
Department of Obstetrics and Genecology, The Third Affiliated Hospital of Sun Yat-sen University.
Ther Clin Risk Manag. 2017 Feb 27;13:279-285. doi: 10.2147/TCRM.S123199. eCollection 2017.
Aldolase A (ALDOA) is a glycolytic enzyme that drives the glycolytic metabolic pathway in mammalian cells. The overexpression of ALDOA was observed in a variety of cancers including clear-cell renal cell carcinoma (ccRCC). However, little was known about the clinicopathological significance and prognostic value of ALDOA in ccRCC patients.
The expression of ALDOA was detected using immunohistochemical staining in 162 formalin-fixed, paraffin-embedded ccRCC sections. Prognostic outcomes correlated with ALDOA were examined using Kaplan-Meier analysis and the Cox proportional hazards model.
In patients with ccRCC, increased cytoplasmic ALDOA expression was positively associated with tumor size (=0.021), TNM stages (=0.034), lymph node metastasis (=0.020), and overall survival (OS) (<0.001). Kaplan-Meier analysis showed that high cytoplasmic expression of ALDOA was associated with a statistically significant lower OS (<0.001). Multivariate analysis demonstrated that ALDOA expression was an independent and significant prognostic factor (HR =3.561, 95% CI =1.715-7.396, =0.001). ALDOA expression was not associated with significant prognostic deference in the subgroups of TNM stage I patients or pT1 patients.
Our results suggest that ALDOA expression is an independent prognostic factor for OS in patients with ccRCC.
醛缩酶A（ALDOA）是一种糖酵解酶，驱动哺乳动物细胞中的糖酵解代谢途径。在包括透明细胞肾细胞癌（ccRCC）在内的多种癌症中均观察到ALDOA的过表达。然而，关于ALDOA在ccRCC患者中的临床病理意义和预后价值知之甚少。
采用免疫组织化学染色检测162例福尔马林固定、石蜡包埋的ccRCC切片中ALDOA的表达。使用Kaplan-Meier分析和Cox比例风险模型检查与ALDOA相关的预后结果。
在ccRCC患者中，细胞质ALDOA表达增加与肿瘤大小（=0.021）、TNM分期（=0.034）、淋巴结转移（=0.020）和总生存期（OS）（<0.001）呈正相关。Kaplan-Meier分析显示，ALDOA的高细胞质表达与统计学上显著较低的OS相关（<0.001）。多变量分析表明，ALDOA表达是一个独立且显著的预后因素（HR =3.561，95%CI =1.715 - 7.396，=0.001）。在TNM I期患者或pT1患者亚组中，ALDOA表达与显著的预后差异无关。
我们的结果表明，ALDOA表达是ccRCC患者OS的独立预后因素。
